58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # Manchester Grand Grand Hall Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist 7:45 AM 08:00AM 12/03/16 AbbVie / Roche Venclexta 32 Hyatt San Diego: D Venetoclax in Acute Myeloid Leukemia San Diego A CD47xCD19 Bispecific Antibody That Remodels the Tumor Microenvironment for Improved Killing and 7:45 AM 08:00AM 12/03/16 Room 5AB Novimmune S.A. NA 44 Convention Center: Provokes a Memory Immune Response to Cancer B Cells San Diego 7:45 AM 08:00AM 12/03/16 Room 6AB Juno JCAR014 CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia 56 Convention Center: San Diego Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical 8:15 AM 08:30AM 12/03/16 Room 6AB AbbVie / J&J Imbruvica 58 Convention Center: Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL Bristol-Myers San Diego 8:30 AM 08:45AM 12/03/16 Room 6AB Squibb / Ono / Opdivo / Imbruvica Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial 59 Convention Center: AbbVie / J&J Manchester Grand Grand Hall Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter 8:30 AM 08:45AM 12/03/16 Amgen romiplostim 65 Hyatt San Diego: B Trial San Diego AstraZeneca / Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical 8:45 AM 09:00AM 12/03/16 Room 6AB acalabrutinib 60 Convention Center: Acerta / Merck Study Seaport Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Manchester Grand BPX-501 8:45 AM 09:00AM 12/03/16 Ballroom Bellicum Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) 72 Hyatt San Diego: (rimiducid) EFGH after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT) Manchester Grand Grand Hall Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of 9:30 AM 09:45AM 12/03/16 AbbVie / Roche Venclexta 97 Hyatt San Diego: A Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models Manchester Grand Grand Hall Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, 9:45 AM 10:00AM 12/03/16 Takeda pevonedistat 98 Hyatt San Diego: A Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML) San Diego Seattle Genetics / Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with 9:45 AM 10:00AM 12/03/16 Room 7AB Adcetris 104 Convention Center: Takeda High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL) Manchester Grand Grand Hall glasdegib (PF- A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated 10:00 AM 10:15AM 12/03/16 Pfizer 99 Hyatt San Diego: A 0449913) Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome San Diego True North TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in 10:15 AM 10:30AM 12/03/16 Room 33 TNT009 94 Convention Center: Therapeutic Patients with Cold Agglutinin Disease Manchester Grand Grand Hall Helsinn / MEI A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not 10:15 AM 10:30AM 12/03/16 pracinostat 100 Hyatt San Diego: A Pharma Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit Manchester Grand Grand Hall Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance 10:30 AM 10:45AM 12/03/16 AbbVie / Roche Venclexta 101 Hyatt San Diego: A to BCL-2 Inhibitor Venetoclax in AML San Diego Room Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow 10:30 AM 10:45AM 12/03/16 Roche / Chugai ACE910 83 Convention Center: 28ABCD Condition Manchester Grand Grand Hall Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with 10:45 AM 11:00AM 12/03/16 AbbVie / Roche Venclexta 102 Hyatt San Diego: A Acute Myeloid Leukemia Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Manchester Grand Grand Hall 10:45 AM 11:00AM 12/03/16 Otsuka ASTX727 (E7727) Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes 114 Hyatt San Diego: C (MDS): Final Data of Phase 1 Study San Diego Room SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in 12:00 PM 12:15PM 12/03/16 Invenux SCD-101 121 Convention Center: 28ABCD Peripheral Blood of Patients with Sickle Cell Disease San Diego Ballroom Halozyme / Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with 12:00 PM 12:15PM 12/03/16 Rituxan 145 Convention Center: 20CD Roche / Biogen Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group San Diego Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic 12:30 PM 12:45PM 12/03/16 Room 29 Shire BAX930 135 Convention Center: Purpura (Upshaw-Schulman Syndrome (USS)) San Diego PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and Is Associated with Several 12:30 PM 12:45PM 12/03/16 Room 31 NA NA 153 Convention Center: Genomic Markers AbbVie / J&J / San Diego Ballroom Celgene Biogen / Imbruvica / Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from 12:45 PM 01:00PM 12/03/16 148 Convention Center: 20CD Roche / Revlimid / Rituxan the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial Halozyme 58th Annual Meeting and Exposition (December 3-6, 2016) Bloomberg Intelligence: ASH Planner Start Time End Time Day Location Room Company (s) Drug (s) Presentation Abstract # San Diego 1:00 PM 01:15PM 12/03/16 Room 30 Portola andexanet alfa Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa 143 Convention Center: Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary San Diego 2:00 PM 02:15PM 12/03/16 Room 29 GlaxoSmithKline eltrombopag Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the 163 Convention Center: Randomized, Placebo-Controlled, Phase III Support Study Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing San Diego Seattle Genetics / 2:15 PM 02:30PM 12/03/16 Room 6AB Adcetris Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza 182 Convention Center: Takeda Study San Diego Marriott Marquis San Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic 2:30 PM 02:45PM 12/03/16 Ballroom Novartis nelarabine 177 Diego Marina: Leukemia and T-Lymphoblastic Lymphoma AB San Diego Bristol-Myers A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic 2:30 PM 02:45 PM 12/03/16 Room 6AB Opdivo / Yervoy Convention Center: Squibb / Ono Malignancies (CheckMate 039) San Diego Specific Inhibition of AKT with ARQ 092, an Orally-Available Selective AKT Inhibitor, Attenuates Acute Vaso- 2:45 PM 03:00PM 12/03/16 Room 7AB ArQule ARQ 092 160 Convention Center: Occlusive Events in Sickle Cell Disease Gilead / Biogen / San Diego Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for 3:15 PM 03:30PM 12/03/16 Room 5AB Roche / Zydelig / Rituxan 192 Convention Center: Relapsed Chronic Lymphocytic Leukemia Halozyme San Diego SGN-CD33A Marriott Marquis San A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly 4:00 PM 04:15PM 12/03/16 Ballroom Seattle Genetics (vadastuximab 211 Diego Marina: Diagnosed Acute Myeloid Leukemia (AML) AB talirine) Marriott Marriott Marquis San Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and 4:00 PM 04:15PM 12/03/16 Grand 11- Novartis CTL119 217 Diego Marina: Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia 13 Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Manchester Grand Grand Hall Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic 4:00 PM 04:15PM 12/03/16 Celgene Revlimid 223 Hyatt San Diego: C Syndrome (MDS): Results of the E2905 Intergroup Study—an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Seaport Manchester Grand 4:00 PM 04:15 PM 12/03/16 Ballroom Celgene Revlimid Final Analysis of Overall Survival from the First Trial 241 Hyatt San Diego: ABCD Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Manchester Grand Grand Hall Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or 4:15 PM 04:30PM 12/03/16 Celgene Revlimid 224 Hyatt San Diego: C Unlikely